{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:39:06Z","timestamp":1759847946857},"reference-count":57,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,1,15]],"date-time":"2007-01-15T00:00:00Z","timestamp":1168819200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Routine CD4 count and HIV viral load monitoring is a financial barrier in developing countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We assessed factors associated with CD4 counts \u2264200\u2003cells\/\u03bcL and detectable viral load in Thai HIV\u2010infected patients receiving antiretroviral therapy (ART) at the HIV Netherlands Australia Thailand Research Collaboration and the Thai Red Cross AIDS Research Centre (HIV\u2010NAT). Univariate and multivariate Cox proportional hazards models for multiple treatment failures were used to determine factors related to CD4 counts \u2264200\u2003cells\/\u03bcL and detectable viral load. Multivariate Cox proportional hazards models for CD4 counts \u2264200\u2003cells\/\u03bcL were developed with and without viral load in order to build models applicable to contexts in which viral load is not available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four hundred and seventeen patients were included in the study. Fifty\u2010four per cent were male, and the median CD4 count and log<jats:sub>10<\/jats:sub> viral load at baseline were 283\u2003cells\/\u03bcL and 4.3\u2003log<jats:sub>10<\/jats:sub>\u2003HIV\u20101 RNA\u2003copies\/mL, respectively. Independent factors related to CD4 count \u2264200\u2003cells\/\u03bcL were CD4 count at baseline [hazards ratio (HR) 0.20\/100\u2003cells\/\u03bcL; 95% confidence interval (CI) 0.17\u20130.23] and changes in CD4 count (HR 0.22\/100\u2003cells\/\u03bcL; 95% CI 0.17\u20130.28). Factors in multivariate models (in which viral load was considered for inclusion) were CD4 count at baseline (HR 0.21\/100\u2003cells\/\u03bcL; 95% CI 0.18\u20130.24), changes in CD4 count (HR 0.25\/100\u2003cells\/\u03bcL; 95% CI 0.19\u20130.32) and detectable viral load (HR 1.94; 95% CI 1.20\u20133.13). Predictive factors (independent of viral load) were triple ART or highly active antiretroviral therapy (HAART) (HR 0.28; 95% CI 0.22\u20130.36) and detectable viral load at baseline (HR 2.96; 95% CI 2.24\u20133.91).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CD4 count at baseline and changes in CD4 count were important in predicting CD4 counts \u2264200\u2003cells\/\u03bcL. Triple ART and detectable viral load at baseline were important in predicting detectable viral load.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2007.00427.x","type":"journal-article","created":{"date-parts":[[2007,1,15]],"date-time":"2007-01-15T18:35:19Z","timestamp":1168886119000},"page":"46-54","source":"Crossref","is-referenced-by-count":12,"title":["Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment"],"prefix":"10.1111","volume":"8","author":[{"given":"P","family":"Srasuebkul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ungsedhapand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Ruxrungtham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MA","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Phanuphak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DA","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MG","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the HIV\u2010NAT study team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03201-2"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1998.tb123370.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.6.450"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001280-00016"},{"key":"e_1_2_5_6_2","first-page":"1194","article-title":"Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland","volume":"315","author":"Egger M","year":"1997","journal-title":"prospective multicentre study. Swiss HIV Cohort Study"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.307.5710.653b"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.301.5640.1629"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1136\/bmj.329.7478.1308-c","article-title":"New 20 year patents threaten to end AIDS drugs for developing countries","volume":"329","author":"Dyer O.","year":"2004","journal-title":"Br Med J"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1040831"},{"key":"e_1_2_5_12_2","first-page":"456","article-title":"Martin government to reintroduce patent changes","volume":"170","author":"Eggertson L.","year":"2004","journal-title":"Cmaj"},{"key":"e_1_2_5_13_2","first-page":"7","article-title":"TRIPS from Doha to Cancun \u2026 to Ottawa","volume":"8","author":"Elliott R.","year":"2003","journal-title":"global developments in access to treatment and Canada's Bill C-56"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7419.832-e"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2004.03041.x"},{"key":"e_1_2_5_16_2","first-page":"222","article-title":"Antiretroviral treatment for adult HIV infection in 2002","volume":"288","author":"Yeni PG","year":"2002","journal-title":"updated recommendations of the International AIDS Society-USA Panel"},{"key":"e_1_2_5_17_2","first-page":"381","article-title":"Antiretroviral therapy in adults","volume":"283","author":"Carpenter CC","year":"2000","journal-title":"updated recommendations of the International AIDS Society-USA Panel"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462011923741"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00009"},{"key":"e_1_2_5_20_2","first-page":"148","article-title":"Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV\u20101\u2010infected adults","volume":"190","author":"Dragsted UB","year":"2004","journal-title":"a EuroSIDA study"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309050-00009"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2003.00156.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200406010-00006"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200304150-00016"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501280-00011"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200204150-00006"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/427695"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00274.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0792-3"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/427878"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007070-00010"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200106010-00003"},{"key":"e_1_2_5_33_2","first-page":"410","article-title":"Indinavir\/ritonavir 800\/100\u2003mg bid and efavirenz 600\u2003mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors","volume":"6","author":"Boyd MA","year":"2005","journal-title":"96-week outcomes of HIV-NAT 009"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501280-00009"},{"key":"e_1_2_5_35_2","first-page":"74","article-title":"CDC revises HIV classification system, AIDS definition","volume":"89","author":"Castro KG","year":"1993","journal-title":"W V Med J"},{"key":"e_1_2_5_36_2","first-page":"790","article-title":"Outcome and predictors of failure of highly active antiretroviral therapy","volume":"179","author":"Wit FW","year":"1999","journal-title":"one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-6-200009190-00007"},{"key":"e_1_2_5_38_2","first-page":"1947","article-title":"Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy","volume":"190","author":"Mocroft A","year":"2004","journal-title":"results from the EuroSIDA Study Group"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201040-00004"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200112070-00006"},{"key":"e_1_2_5_41_2","first-page":"1123","article-title":"Predictors of virological success and ensuing failure in HIV\u2010positive patients starting highly active antiretroviral therapy in Europe","volume":"160","author":"Paredes R","year":"2000","journal-title":"results from the EuroSIDA study"},{"key":"e_1_2_5_42_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00002030-199902250-00009","article-title":"Virological response to protease inhibitor therapy in an HIV clinic cohort","volume":"13","author":"Staszewski S","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922299309676"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199816000-00011"},{"key":"e_1_2_5_45_2","first-page":"F35","article-title":"HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic","volume":"13","author":"Deeks SG","year":"1999","journal-title":"response to both initial and salvage therapy"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199811000-00005"},{"key":"e_1_2_5_47_2","first-page":"201","article-title":"The use of and response to second\u2010line protease inhibitor regimens","volume":"15","author":"Mocroft A","year":"2001","journal-title":"results from the EuroSIDA study"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007070-00011"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001280-00009"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16589-6"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-4-200402170-00007"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2001.00340.x"},{"key":"e_1_2_5_53_2","first-page":"452","article-title":"Virologic, immunologic, and clinical response to highly active antiretroviral therapy","volume":"32","author":"Moore AL","year":"2003","journal-title":"the gender issue revisited"},{"key":"e_1_2_5_54_2","first-page":"197","article-title":"Gender and clinical outcomes after starting highly active antiretroviral treatment","volume":"29","author":"Moore AL","year":"2002","journal-title":"a cohort study"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000163934.22273.06"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103083441003"},{"key":"e_1_2_5_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200008150-00013"},{"key":"e_1_2_5_58_2","unstructured":"Bureau of East Asian and Pacific Affairs.Background Note Thailand.http:\/\/state.gov\/r\/pa\/ei\/bgn\/2814.htm2005."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2007.00427.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2007.00427.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T02:19:17Z","timestamp":1696904357000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2007.00427.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1468-1293.2007.00427.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2007.00427.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}